StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Down 4.3 %

NASDAQ CHEK opened at $0.86 on Thursday. The company has a 50-day moving average price of $1.09 and a two-hundred day moving average price of $1.32. The stock has a market cap of $5.04 million, a price-to-earnings ratio of -0.29 and a beta of 0.16. Check-Cap has a 52 week low of $0.56 and a 52 week high of $3.45.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.